IP Library Granted Patent US 10,190,141
Granted Patent B2
US 10,190,141 · App. 15/101,474 · Granted Jan 29, 2019

Compositions and methods for making (R)-Reticuline and precursors thereof

Inventors: Peter James Facchini (Calgary, CA); Scott Cameron Farrow (Calgary, CA); Guillaume Arthur Welch Beaudoin (Calgary, CA)
Assignee: Epimeron Inc.
C12P17/12A01H1/06C12N9/0006C12N9/1085C12N15/8218C12N15/8243C12Y101/01247C12Y205/01059
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,190,141
App. No.
15/101,474
Granted
Jan 29, 2019
Kind
B2
Abstract

Methods that may be used for the manufacture of the chemical compound (R)-Reticuline and synthesis precursors thereof. Compositions useful for the synthesis (R)-Reticuline and synthesis precursors are also provided.

Claims (26)

1. A method of making (R)-Reticuline or a precursor of (R)-Reticuline comprising

(a) contacting a benzylisoquinoline derivative with a microorganism expressing a heterologous enzyme capable of converting the benzylisoquinoline derivative to (R)-Reticuline or an (R)-Reticuline precursor, wherein said enzyme is a fusion protein of CYP450 and AKR and comprises an amino acid sequence that is at least 85% identical to SEQ.ID NO: 323; and

(b) growing said microorganism to produce (R)-Reticuline or a precursor of (R)-Reticuline.

2. A method for preparing (R)-Reticuline or an (R)-Reticuline precursor comprising:

(a) providing a chimeric nucleic acid sequence comprising as operably linked components:

(i) a first nucleic acid sequence encoding a CYP450 polypeptide;

(ii) a second nucleic acid sequence encoding an AKR polypeptide; and

(iii) one or more nucleic acid sequences capable of controlling expression in a host cell;

(b) introducing said chimeric nucleic acid sequence into said host cell and growing said host cell to produce CYP450 and AKR and to produce (R)-Reticuline or the (R)-Reticuline precursor, wherein said CYP450 and AKR form a fusion protein comprising an amino acid sequence that is at least 85% identical to SEQ.ID NO: 323; and

(c) recovering (R)-Reticuline or the (R)-Reticuline precursor.

3. A recombinant expression vector suitable for expression in a host cell comprising as operably linked components:

(i) a nucleic acid sequence capable of controlling expression in said host cell; and

(ii) a nucleic acid sequence encoding CYP450 and AKR,

wherein said CYP450 and AKR form a fusion protein comprising an amino acid sequence that is at least 85% identical to SEQ.ID NO: 323.

4. The method of claim 1 , wherein said method makes (R)-Reticuline.

5. The method of claim 1 , wherein said microorganism is a yeast.

6. The method of claim 1 , wherein said fusion protein of CYP450 and AKR comprises an amino acid sequence that is at least 95% identical to SEQ.ID NO: 323.

7. The method of claim 1 , further comprising converting said (R)-Reticuline or (R)-Reticuline precursor into salutaridine, salutaridine-7-O-acetate, or thebaine.

8. The method of claim 2 , wherein said host cell is a plant cell, bacterium, or yeast.

9. The method of claim 2 , wherein said method makes (R)-Reticuline.

10. The method of claim 2 , further comprising converting said (R)-Reticuline or (R)-Reticuline precursor into salutaridine, salutaridine-7-O-acetate, or thebaine.

11. The recombinant expression vector of claim 3 , wherein said host cell is a plant cell, bacterium, or yeast.

12. The method of claim 2 , wherein said fusion protein of CYP450 and AKR comprises an amino acid sequence that is at least 95% identical to SEQ.ID NO: 323.

13. The method of claim 2 , wherein said host cell is a yeast.

14. The recombinant expression vector of claim 3 , wherein said fusion protein of CYP450 and AKR comprises an amino acid sequence that is at least 95% identical to SEQ.ID NO: 323.

15. The recombinant expression vector of claim 3 , wherein said host cell is a yeast.

Assignments (7)
SECURITY INTEREST Recorded Aug 29, 2025
From: ANTHEIA, INC.
To: HERCULES CAPITAL, INC., AS AGENT
Reel/Frame 072750/0812 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2025
From: WILLOW BIOSCIENCES, INC.
To: ANTHEIA, INC.
Reel/Frame 070785/0704 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 3, 2021
From: ELESZTO GENETIKA, INC.
To: ANTHEIA, INC.
Reel/Frame 055485/0062 →
MERGER Recorded Oct 22, 2020
From: WILLOW BIOSCIENCES, INC.; EPIMERON INCORPORATED; VINDOLON INCORPORATED; SERTURNER CORPORATION
To: WILLOW BIOSCIENCES, INC.
Reel/Frame 054139/0229 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 22, 2020
From: WILLOW BIOSCIENCES, INC.
To: ELESZTO GENETIKA INC.
Reel/Frame 054137/0202 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 14, 2016
From: FACCHINI, PETER J.; FARROW, SCOTT; BEAUDOIN, GUILLAUME
To: UTI LIMITED PARTNERSHIP
Reel/Frame 039735/0921 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 14, 2016
From: UTI LIMITED PARTNERSHIP
To: EPIMERON INC.
Reel/Frame 039736/0055 →
Continuity (3)
Provisional Application 61911759 · Dec 4, 2013
Provisional Application 62050399 · Sep 15, 2014
Related Publication 20160312256A1 · Oct 27, 2016
Cited By (2)
US 12,480,131 US 12,497,638